Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors

por Floros, Konstantinos V., Jacob, Sheeba, Kurupi, Richard, Fairchild, Carter K., Hu, Bin, Puchalapalli, Madhavi, E. Koblinski, Jennifer, Dozmorov, Mikhail G., Boikos, Sosipatros A., Scaltriti, Maurizio, Faber, Anthony C.
Publicado 2021

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

por Cai, Jinyang, Jacob, Sheeba, Kurupi, Richard, Dalton, Krista M., Coon, Colin, Greninger, Patricia, Egan, Regina K., Stein, Giovanna T., Murchie, Ellen, McClanaghan, Joseph, Adachi, Yuta, Hirade, Kentaro, Dozmorov, Mikhail, Glod, John, Boikos, Sosipatros A., Ebi, Hiromichi, Hao, Huaixiang, Caponigro, Giordano, Benes, Cyril H., Faber, Anthony C.
Publicado 2022

Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1

por Kurupi, Richard, Floros, Konstantinos V., Jacob, Sheeba, Chawla, Ayesha T., Cai, Jinyang, Hu, Bin, Puchalapalli, Madhavi, Coon, Colin M., Khatri, Rishabh, Crowther, Giovanna Stein, Egan, Regina K., Murchie, Ellen, Greninger, Patricia, Dalton, Krista M., Ghotra, Maninderjit S., Boikos, Sosipatros A., Koblinski, Jennifer E., Harada, Hisashi, Sun, Yue, Morgan, Iain M., Basu, Devraj, Dozmorov, Mikhail G., Benes, Cyril H., Faber, Anthony C.
Publicado 2022